Two treatments sharing one drug
The same molecule, botulinum toxin type A, sits behind two entirely different treatments, and the sharing of a brand name has generated a decade of patient confusion. Cosmetic toxin relaxes specific expression muscles at modest doses to soften lines. Migraine toxin is a preventive medical therapy, injected across the scalp, forehead, temples, neck and shoulders at substantially higher total doses, on a repeating cycle, with the aim of reducing how many days a month a patient loses to headache.
Patients understandably blur the two. Some hope their cosmetic forehead treatment will fix their migraines; some migraine patients wander into cosmetic clinics asking for "Botox for my headaches"; and some clinics, less understandably, allow the ambiguity to stand because it sells appointments. The distinction is worth drawing sharply, because it determines diagnosis, dose, technique, follow-up and who is competent to provide it.
What chronic migraine actually means
The evidence for toxin applies to a specific diagnosis: chronic migraine, conventionally defined as headache on 15 or more days per month for more than three months, of which at least eight days have migraine features. That is a different condition, in scale and management, from episodic migraine, the occasional severe attacks most people mean by the word, and different again from tension-type headache or medication-overuse headache, which commonly coexists and complicates the picture.
The distinction is not pedantry. Trials in episodic migraine and tension-type headache have not shown the same benefit, which is why the licensed and recommended use is chronic migraine specifically. A patient who has never had their headache days counted, their medication use reviewed, or their diagnosis formally made has not yet reached the starting line for this treatment. That work-up is medicine, not aesthetics.
The evidence and the NICE position
Large randomised controlled trials in chronic migraine, evaluated by regulators and by NICE, showed that repeated cycles of botulinum toxin reduce headache days versus placebo, modestly on average but meaningfully for a subset of patients. Following that appraisal, NICE recommends botulinum toxin type A as an NHS treatment option for chronic migraine in adults who have not responded to at least three prior preventive medications, with treatment stopped if the response is inadequate or the condition converts to episodic migraine. Medication overuse is expected to be addressed as part of care.
Three features of that position deserve emphasis. The recommendation is conditional, sitting at a defined point in a treatment pathway rather than first-line. The benefit is averaged and probabilistic, some patients respond well, some not at all, and response is assessed over two to three treatment cycles. And the framework assumes a clinician who can diagnose, count, review medication and stop treatment when criteria say so. All three features presuppose ongoing medical oversight of exactly the kind a walk-in cosmetic appointment does not provide.
NICE recommends toxin for chronic migraine at a defined point in a medical pathway. There is no pathway on a cosmetic price list.
The medical protocol versus the cosmetic pattern
Migraine treatment follows a standardised protocol derived from the major trials: injections across roughly 31 sites spanning the forehead, temples, back of the head, neck and shoulders, at a total dose several times larger than a typical cosmetic session, repeated every 12 weeks. The distribution is fixed with optional additional sites at painful areas; it is emphatically not a matter of treating wherever lines happen to be.
| Cosmetic toxin | Migraine protocol | |
|---|---|---|
| Purpose | Soften expression lines | Reduce monthly headache days |
| Sites | A few per area, individualised | About 31 standardised sites across head, neck and shoulders |
| Total dose | Modest | Several times higher |
| Cycle | As results fade, often 3 to 4 months | Fixed 12-week cycles with formal response review |
| Outcome measure | Appearance | Headache diary |
A cosmetic forehead treatment incidentally relaxes some muscles that feature in the migraine protocol, and some patients notice fewer headaches afterwards. That anecdote is real but it is not the treatment the evidence supports, at a fraction of the dose and coverage. Conversely, a patient given the full migraine protocol gets, incidentally, a very smooth forehead. The direction of travel matters: dose and distribution should follow the diagnosis.
Who should treat migraine with toxin
The appropriate setting is a headache service or a clinician working within one: consultant neurologists, headache specialists, and specialist nurses trained in the protocol, with the diagnosis established, other preventives tried, medication overuse addressed, and a headache diary running before the first needle. In the NHS this is how the treatment is commissioned. Privately, the same standard should apply, and the register checks are the patient's tool: a doctor's specialism is verifiable through the GMC register, which shows specialist registration in neurology.
What should give a patient pause is the inversion of that model: a practitioner whose training is cosmetic offering "migraine Botox" as a menu item, without diagnosis, diary, pathway or the intention of stopping when criteria are unmet. However skilled the injecting, the medicine around it is missing, and the medicine is the treatment. The general problem of clinical language outrunning clinical governance in this sector is one we cover in what "aesthetic clinic" means in UK law.
Where cosmetic clinics fit legitimately
None of this makes cosmetic clinics villains, and there are honourable overlaps. Doctor-led aesthetic practices sometimes include clinicians who also hold NHS roles in relevant specialties. A cosmetic patient describing frequent headaches deserves to be told the difference between the treatments and pointed towards their GP for referral, and a good clinic does exactly that. And toxin delivered for genuinely cosmetic reasons, at cosmetic doses, to a patient who also has migraines, is legitimate, provided nobody pretends it is migraine therapy. The masseter offers a parallel: a muscle treated for both medical symptoms and appearance, where the boundary questions are similar and which we examine in our masseter guide.
The line is crossed when marketing sells a medical indication without the medical apparatus. A useful screen: ask who will make the diagnosis, what happens if you do not respond after two cycles, and how your headache days will be counted. A migraine service answers instantly. A menu does not.
Cost, access and the practical route in
The NHS route runs through a GP referral to neurology or a specialist headache clinic, with toxin available under the NICE criteria once three preventives have failed; waiting times vary considerably by region. Privately, specialist headache clinics offer the full protocol at observed 2026 prices of roughly £400 to £800 per cycle, repeated every 12 weeks, which is materially more than the £150 to £450 cosmetic sessions in our price survey because the dose and time involved are materially greater. Newer preventive drug classes for migraine also now exist, with their own NICE appraisals, and a specialist will weigh toxin against them. That comparison, like everything else in this pathway, is a medical judgement, which is rather the point.